Controlo da sintomatologia para o aumento da adesão à terapêutica no tratamento da hepatite C
Resumo
Hepatitis C has an overall prevalence of approximately 3%, which equates to approximately 170 million infected individuals. Owing to
the burden of the disease has been an area in constant updating, particularly in terms of new therapies. Currently, the standard treatment is the
association of pegylated interferon and ribavirin for a period of 24-72 weeks. The fact of being a long treatment with many side effects often leads to
a lack of adherence by the patient and consequently decreases the response. According to Larrey et al (2011) “Therapeutic education by a specialized
nurse increases the response of patients with hepatitis C to therapy, particulary in difficult-to-treat patients.”
The aim of the study was to identify the side effects with higher incidence in patients treated for hepatitis C virus (HCV) and strategies for
their management.
A retrospective study was conducted with review of medical and nursing records in clinical process. The sample includes all patients who started
treatment during the year 2011 in Hospital Prof. Dr. Fernando Fonseca. The data were then statistically analyzed with the program “SPSS” version
20. In the sample (n = 30) the majority of side effects reported are included in the group of general symptoms (93.3%), followed by disturbances of
metabolism and nutrition (76.7%) and musculoskeletal disorders (66.7%), along with psychiatric disorders.
The new therapies for hepatitis C seek higher success rates and fewer side effects. Nowadays, there are more effective therapeutic but also with more
and more severe side effects who may themselves determine the end of treatment. The side effects have to be approached in a multidisciplinary way.
Continued and systematic monitoring, including the patient as a member of team will ensure efficient management of side effects, increase compliance and a high rate of success.
the burden of the disease has been an area in constant updating, particularly in terms of new therapies. Currently, the standard treatment is the
association of pegylated interferon and ribavirin for a period of 24-72 weeks. The fact of being a long treatment with many side effects often leads to
a lack of adherence by the patient and consequently decreases the response. According to Larrey et al (2011) “Therapeutic education by a specialized
nurse increases the response of patients with hepatitis C to therapy, particulary in difficult-to-treat patients.”
The aim of the study was to identify the side effects with higher incidence in patients treated for hepatitis C virus (HCV) and strategies for
their management.
A retrospective study was conducted with review of medical and nursing records in clinical process. The sample includes all patients who started
treatment during the year 2011 in Hospital Prof. Dr. Fernando Fonseca. The data were then statistically analyzed with the program “SPSS” version
20. In the sample (n = 30) the majority of side effects reported are included in the group of general symptoms (93.3%), followed by disturbances of
metabolism and nutrition (76.7%) and musculoskeletal disorders (66.7%), along with psychiatric disorders.
The new therapies for hepatitis C seek higher success rates and fewer side effects. Nowadays, there are more effective therapeutic but also with more
and more severe side effects who may themselves determine the end of treatment. The side effects have to be approached in a multidisciplinary way.
Continued and systematic monitoring, including the patient as a member of team will ensure efficient management of side effects, increase compliance and a high rate of success.
Texto Completo:
PDFApontamentos
- Não há apontamentos.